RCT | Dysphagia-optimized intensity-modulated radiotherapy better preserves swallowing function in pharyngeal cancer patients

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial – The Lancet Oncology

Commentaries:

Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer – The ASCO Post

Radiation approach improves swallowing in head, neck cancer – MDedge

Commentary on Twitter

NOW OF: The (DARS) phase 3 RCT investigates if dysphagia-optimised intensity-modulated radiotherapy (IMRT) reduces radiation dose to the dysphagia and aspiration related structures and improves swallowing function compared with standard IMRT.#hncsmhttps://t.co/CzpxsNxx1N pic.twitter.com/xNgfm43tHE

— The Lancet Oncology (@TheLancetOncol) July 7, 2023